Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) priced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $5.00 per share, less underwriting discounts and commissions. In addition, AGTC has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of its common stock at the public offering price per share, less the underwriting discounts and commissions.
The gross proceeds from the offering are expected to be $32,500,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by AGTC.
Wells Fargo Securities, LLC and Wedbush Securities Inc. acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as lead manager for the offering. Janney Montgomery Scott LLC and Roth Capital Partners acted as co-managers for the offering.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.
The Davis Polk corporate team included partner Yasin Keshvargar (Picture) and associates David Li and Stephen H. Karp. The intellectual property and technology team included counsel Bonnie Chen and associate Daniel P. Kearney. Partner Patrick E. Sigmon provided tax advice
Involved fees earner: Bonnie Chen – Davis Polk & Wardwell; Stephen Karp – Davis Polk & Wardwell; Daniel Kearney – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; David Li – Davis Polk & Wardwell; Patrick Sigmon – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;